Pharmacokinetics and Pharmacodynamics of Prusogliptin (DBPR108), a Once-Daily Dipeptidyl Peptidase-4 Inhibitor, in Patients with Type 2 Diabetes
Clinical Pharmacokinetics · 2025
DOI: 10.1007/s40262-025-01501-8 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacokinetics, 2025. Verfasst von Wenfang Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Center, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing, 100029, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSPC Zhongqi Pharmaceutical Technology(Shijiazhuang)Co.,Ltd..
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND AND OBJECTIVE: DBPR108 (prusogliptin) is a novel, orally bioavailable dipeptidyl peptidase-4 (DPP-4) inhibitor. This study investigated the pharmacokinetics and pharmacodynamic characteristics of DBPR108 tablets in patients with type 2 diabetes. METHODS: In this randomized, parallel-group, open-label, phase I study, Chinese adults with type 2 diabetes, glycated hemoglobin of 7.0-9.5%, and body mass index of 19-35 kg/m2 were randomized 1:1:1 to once-daily DBPR108 50-, 100-, or 200-mg tablet groups. The primary endpoints included pharmacokinetic and pharmacodynamic characteristics after a single dose and multiple doses of DBPR108. RESULTS: In total, 30 patients were randomized with 10 patients in each group. DBPR108 was quickly absorbed with median time to reach the maximum plasma concentration of 1.5-4 h at steady state. Exposure to DBPR108 at steady-state increased dose proportionally with mean maximum steady-state plasma DBPR108 concentration during dosage intervals of 119, 256, and 567 ng/mL in the 50-, 100-, and 200-mg groups, respectively. Accumulation ratio of DBPR108 ranged from 0.85 to 1.3, and steady state was reached after four continuous daily doses. After multiple doses of DBPR108, maximum inhibitory efficacy of DPP-4 increased with higher dose levels ranging from 62.1 to 89.4%. Active glucagon-like peptide-1 levels increased after DBPR108 administration. In addition, six patients experienced treatment-emergent adverse events without leading to treatment interruption or discontinuation. CONCLUSIONS: DBPR108 was well tolerated in Chinese patients with type 2 diabetes, and both the pharmacokinetic and pharmacodynamic profiles support once-daily dosage regimens of DBPR108 in future studies. TRIAL REGISTRATION: ClinicalTrials.gov (NCT05146869); registered 23 November 2021.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Center, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing, 100029, China.
- Clinical Trial Center, The First Affiliated Hospital of Bengbu Medical University, No. 287, Changhuai Road, Bengbu, 233004, China.
- Clinical Division, CSPC Pharmaceutical Group Co., Ltd., Shijiazhuang, China.
- Clinical Trial Center, The First Affiliated Hospital of Bengbu Medical University, No. 287, Changhuai Road, Bengbu, 233004, China. 158169847@qq.com.
- Clinical Pharmacology Center, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, Chaoyang District, Beijing, 100029, China. jingshan@anzhengcp.com.
ORCID-Profile: Shan Jing
Förderung
- CSPC Zhongqi Pharmaceutical Technology(Shijiazhuang)Co.,Ltd.
Zitieren
APA
Liu, W., Yang, K., Lin, Y., Lu, C., Liu, J., Zhou, H., Wang, J., Zhang, T., Yao, L., Qi, H., Zhang, X., Jia, R., Li, X., & Jing, S. (2025). Pharmacokinetics and Pharmacodynamics of Prusogliptin (DBPR108), a Once-Daily Dipeptidyl Peptidase-4 Inhibitor, in Patients with Type 2 Diabetes. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-025-01501-8
Vancouver
Liu W, Yang K, Lin Y, Lu C, Liu J, Zhou H, et al. Pharmacokinetics and Pharmacodynamics of Prusogliptin (DBPR108), a Once-Daily Dipeptidyl Peptidase-4 Inhibitor, in Patients with Type 2 Diabetes. Clinical Pharmacokinetics. 2025. doi:10.1007/s40262-025-01501-8
BibTeX
@article{Liu2025,
author = {Liu, Wenfang and Yang, Kexu and Lin, Yang and Lu, Chunyan and Liu, Jingyi and Zhou, Huan and Wang, Juan and Zhang, Tianhao and Yao, Lingli and Qi, Huanhuan and Zhang, Xiaofang and Jia, Rui and Li, Xiaoli and Jing, Shan},
title = {Pharmacokinetics and Pharmacodynamics of Prusogliptin (DBPR108), a Once-Daily Dipeptidyl Peptidase-4 Inhibitor, in Patients with Type 2 Diabetes},
journal = {Clinical Pharmacokinetics},
year = {2025},
doi = {10.1007/s40262-025-01501-8}
}
EUVIMED